

INVESTIGATORS' WORKSHOP

15th SPORE




Image copyright Dennis Kunkle Microscopy, Inc.

**JULY 7-10, 2007
BALTIMORE MARRIOTT WATERFRONT
PROGRAM BOOK**

**Translational cancer research...
innovation through teamwork**

National Cancer Institute

ORGAN SYSTEMS BRANCH

U.S. DEPARTMENT
OF HEALTH AND
HUMAN SERVICES

National Institutes
of Health



Saturday, July 7

9:00 a.m. - 5:00 p.m. *Harborside Ballroom A-B*
Strategies for Implementing Biomarker
Evidence in Translational Cancer Research

2:00 p.m. - 6:00 p.m. *Harborside Ballroom D*
SPORE Directors' Meeting (*invitation only*)

Sunday, July 8

7:00 a.m. - 8:00 a.m.
Breakfast (*on your own*)

7:00 a.m. - 7:00 p.m. *Grand Registration Desk*
Registration

8:00 a.m. - 11:30 a.m. *Grand Ballroom V-VI*
Plenary Session I

11:30 a.m. - 2:00 p.m. *Harborside Ballroom*
Poster Setup

12:30 p.m. - 2:00 p.m.
Lunch Break (*on your own*)

2:00 p.m. - 6:00 p.m.

Organ Site Breakout Sessions I

- Bladder *Waterview A-B*
- Brain *Laurel A-B*
- Breast *Grand Ballroom II-III*
- GI/Pancreas *Dover A-C*
- Head & Neck and Cervical *Laurel C-D*
- Hematological Malignancies (Leukemia, Lymphoma, Myeloma) *Grand Ballroom IV*
- Kidney *Waterview C-D*
- Lung *Essex A-C*
- Ovarian *Kent A-C*
- Prostate *Grand Ballroom VIII-IX*
- Skin *Grand Ballroom I*

6:00 p.m. - 8:00 p.m. *Harborside Ballroom Foyer*
"Opportunities for Networking & Collaboration"
Reception (*prepaid fee event*)

Monday, July 9

7:00 a.m. - 8:00 a.m.

Breakfast *(on your own)*

7:00 a.m. - 7:00 p.m.

Grand Registration Desk

Registration

8:00 a.m. - 10:00 a.m.

Grand Ballroom V-VI

Plenary Session II

10:00 a.m. - 12 noon

Grand Ballroom V-VI

Models for Collaborations and Partnerships

12 noon - 1:30 p.m.

Lunch Break *(on your own)*

12 noon - 2:00 p.m.

Grand Ballroom II-III

SPORE Directors' and Patient Advocates'

Working Luncheon *(invitation only)*

1:30 p.m. - 3:30 p.m.

Concurrent Poster Discussion Sessions I

- Biomarkers I *Grand Ballroom V*
- Molecular Targets and Novel Therapies I *Grand Ballroom VI*
- New Technologies & Methodologies in Translational Research I *Grand Ballroom VIII-IX*

3:30 p.m. - 5:30 p.m.

Concurrent Poster Discussion Sessions II

- Biomarkers II *Grand Ballroom V*
- Molecular Targets and Novel Therapies II *Grand Ballroom VI*
- New Technologies & Methodologies in Translational Research II *Grand Ballroom VIII-IX*

5:30 p.m. - 8:30 p.m.

Harborside Ballroom Foyer

Poster Session and "Meet the Author"

Buffet Dinner *(prepaid fee event)*

8:30 p.m.

Harborside Ballroom

Poster Take-down

Tuesday, July 10

7:00 a.m. - 8:00 a.m.

Breakfast *(on your own)*

7:00 a.m. - 12 noon

Grand Registration Desk

Registration

8:00 a.m. - 12 noon

Organ Site Breakout Sessions II

- Bladder *Waterview A-B*
- Brain *Laurel A-B*
- Breast *Grand Ballroom II-III*
- GI/Pancreas *Dover A-C*
- Head & Neck and Cervical *Laurel C-D*
- Hematological Malignancies (Leukemia, Lymphoma, Myeloma) *Grand Ballroom IV*
- Lung *Essex A-C*
- Ovarian *Kent A-C*
- Prostate *Grand Ballroom VIII-IX*
- Skin *Grand Ballroom I*
- Uterine *Waterview C-D*

12 noon

Workshop Adjournment

Internet and Speaker Ready Rooms

2:00 p.m. - 6:00 p.m.

Saturday, July 7

7:00 a.m. - 7:00 p.m.

Sunday, July 8

7:00 a.m. - 7:00 p.m.


Monday, July 9

7:00 a.m. - 12 noon


Tuesday, July 10

Internet Room - *Atlantic*
Speaker Ready Room - *Bristol*


Grand Ballroom



Harborside Ballroom



Waterview Ballroom



Entrance to the Waterview Ballroom is from a designated elevator in the Grand Ballroom Foyer. Please refer to the Grand Ballroom Level Floorplan.



Welcome to the 15th SPORE Investigators' Workshop, highlighting the SPORE Program and its mission to expedite the translation of scientific knowledge into potential treatments. The dedication and commitment of scientists like you, gathering to share knowledge and expertise, help us build a solid foundation to advance the mission of the National Cancer Institute (NCI).

This year's workshop will delve into innovative approaches and exciting new findings since the last assembly. The 15th anniversary is also an occasion for reflection and for assessing the current state of translational cancer research. Scientists and clinician scientists, whether working in our research universities or in the pharmaceutical or biotechnology industries, recognize that the process of developing new therapies is too costly and takes much too long. SPORE investigators will be joined by members from industry, foundations, academia, and other stakeholders involved in the drug discovery process to discuss the steps needed to address these critical issues. It is recognized by all that developing and establishing novel therapies require an equal effort in the development of therapeutic markers appropriate for the agent or the regimen of treatment.

This year's agenda includes *Organ Site Breakout Sessions* with their respective investigators developing strategies to build on prior successes. The *Models for Collaborations and Partnership Session* features an extension of last year's intellectual property management session and promises to enlighten as well as motivate. *Plenary Sessions I and II* will offer insights into NCI and SPORE accomplishments, as best illustrated by the work of Drs. Chinnaiyan and Bast, this year's awards recipients. The *Concurrent Poster Discussion Sessions* are the centerpiece of this workshop, highlighting outstanding research efforts. This will be followed by a Meet the Author Poster Session, favored for the one-on-one dialogue.

I welcome all of you to the 15th SPORE Investigators' Workshop and thank you for your dedication and commitment to continuing our joint efforts to ensure a SPORE program of exceptional scientific excellence, and a program that will continue to provide leadership in translational science.

With warmest regards,



John E. Niederhuber, M.D.
Director
National Cancer Institute

15th SPORE Investigators' Workshop

The primary goal of the Workshop is to advance translational cancer research by expanding collaborations between SPORE investigators, NCI networks, industry, special guests, patient and cancer research advocates, and NCI and NIH staff. The SPORE Workshop is the culmination of efforts from basic, applied, and clinical research scientists to share data, assess research strategies, identify new research opportunities, and determine priorities for research that are most likely to reduce cancer incidence and mortality and improve cancer patient management as well as health outcomes for those populations at risk.

Strategies for Implementing Biomarker Evidence in Translational Cancer Research

9:00 a.m. - 2:00 p.m.

Harborside Ballroom A-B

Welcome for New SPORE Patient Advocates

12 noon - 1:45 p.m.

Dover A-C

Patient Advocate Training: Science in SPOREs

2:00 p.m. - 5:30 p.m.

Dover A-C

**SPORE Directors' Meeting
(invitation only)**

2:00 p.m. - 6:00 p.m.

Harborside Ballroom D

Strategies for Implementing Biomarker Evidence in Translational Cancer Research
Breakout I: Quality Systems for Biomarker Data Accuracy

2:00 p.m. - 5:00 p.m.

Essex A-B

Strategies for Implementing Biomarker Evidence in Translational Cancer Research

Breakout II: Assessing Biologic Evidence: Multidisciplinary Considerations

2:00 p.m. - 5:00 p.m.

Laurel A-B

Strategies for Implementing Biomarker Evidence in Translational Cancer Research

Breakout III: Enhancing Inference From Clinical Studies With Biomarker Data

2:00 p.m. - 5:00 p.m.

Kent A-B

***Ella* Project Investigators' Meeting
(closed meeting)**

6:00 p.m. - 8:00 p.m.

Salon II

**Strategies for Implementing Biomarker Evidence in Translational Cancer Research: Co-chairs' Meeting
(closed meeting)**

7:00 p.m. - 9:00 p.m.

Boardroom

Breakfast (*on your own*)**7:00 a.m. - 8:00 a.m.****Registration****7:00 a.m. - 7:00 p.m.****Grand Registration Desk****NCI Center for Bioinformatics Booth
Learning Center****8:00 a.m. - 7:00 p.m.****Grand Registration Foyer****Plenary Session I****8:00 a.m. - 11:30 a.m.****Grand Ballroom V-VI**

This session officially opens the 15th SPORE Investigators' Workshop by welcoming all participants. The focus of the Workshop is on seizing new opportunities and furthering translational cancer research. The program will include presentations by NCI leadership and translational focus groups. At this Plenary Session, recognition will be given to Dr. Robert Bast, University of Texas M.D. Anderson Cancer Center Ovarian SPORE, as recipient of the SPORE Leadership Award, and Dr. Arul Chinnaiyan, University of Michigan Prostate SPORE, as recipient of the SPORE Outstanding Investigator Award. Dr. Frank McCormick, University of California, San Francisco, our keynote speaker, will set the tone for the Workshop and invite participants to join in discussions pushing the boundaries of translational cancer research.

8:00 a.m. **Welcome**
Jorge Gomez, National Cancer Institute

8:10 a.m. **Director's Update**
Ernest Hawk, National Cancer Institute

8:40 a.m. **Report on the SPORE Directors'
Retreat**
*John Minna, University of Texas
Southwestern Medical Center*

8:55 a.m. **Addressing Cancer Health Disparities
Through Translational Research:
Training, Research, and Partnership
Opportunities**
*Sanya Springfield, National Cancer
Institute*

Awards Ceremony

- 9:10 a.m. ***Biomarkers and SPOREs:
Opportunities and Challenges***
*Robert Bast, University of Texas M.D.
Anderson Cancer Center*
- 9:30 a.m. ***Recurrent Gene Fusions in Prostate
Cancer: A Discovery Made Possible
Through the SPORE Program***
Arul Chinnaiyan, University of Michigan
- 9:50 a.m. **Break**
- 10:00 a.m. **The Success and Failure of Targeted
Therapies**
*Frank McCormick, University of California,
San Francisco*
- 10:30 a.m. **Deliberations on Strategies for
Implementing Biomarker Evidence in
Translational Cancer Research**
*George Klee, Mayo Clinic
Garnet Anderson, Fred Hutchinson Cancer
Research Center*
- 10:45 a.m. **caBIG™ the Enterprise**
*Kenneth Buetow, National Cancer
Institute*
- caBIG™ From an End-User
Perspective**
*Laura Esserman, University of California,
San Francisco*

**Patient Advocate Training: Clinical Trials
and How You Can Help****11:30 a.m. - 1:30 p.m.****Dover A-C****Poster Setup in Harborside Ballroom****11:30 a.m. - 2:00 p.m.****Harborside Ballroom****Session by Asuragen: Applications of
RNA as Diagnostic Analytes****11:30 a.m. - 2:00 p.m.****Heron**

Prostate SPORE Directors' Meeting (closed meeting)

12 noon - 2:00 p.m.

Boardroom

Lunch Break (on your own)

12:30 p.m. - 2:00 p.m.

Organ Site Breakout Sessions I

2:00 p.m. - 6:00 p.m.

These breakout sessions will allow organ site programs to discuss (1) the most important recent scientific advancements, (2) opportunities and technologies that can be used to advance the field, (3) collaborations with other SPORE or NCI programs and networks, and (4) infrastructures needed to support InterSPORE collaborations, and to propose future activities.

Bladder

Waterview A-B

Chair: Colin Dinney, University of Texas M.D. Anderson Cancer Center

NIH Facilitator: Gary Kelloff, National Cancer Institute

2:00 p.m. **International Tissue Array—Update**
Frederic Waldman, University of California, San Francisco

2:15 p.m. **Discussion**

2:30 p.m. **Biological Endpoints**
Richard Cote, University of Southern California
Xifeng Wu, University of Texas M.D. Anderson Cancer Center
Frederic Waldman, University of California, San Francisco

3:30 p.m. **Discussion**

3:45 p.m. **Break**

3:55 p.m. **iCURE Grant Proposal**
Colin Dinney, University of Texas M.D. Anderson Cancer Center

- 4:10 p.m. **Discussion**
- 4:25 p.m. **Data Collection**
Randall Millikan, University of Texas M.D. Anderson Cancer Center
- 4:40 p.m. **Discussion**
- 4:55 p.m. **Perioperative Clinical Trials**
David Quinn, University of Southern California
Susan Groshen, University of Southern California
- 5:15 p.m. **Discussion**
- 5:30 p.m. **Screening Study Update**
H. Barton Grossman, University of Texas M.D. Anderson Cancer Center
- 5:45 p.m. **Discussion**

Brain**Laurel A-B**

- Chair: Mitchel Berger, University of California, San Francisco*
- NIH Facilitators: Jane Fountain, National Institute of Neurological Disorders and Stroke*
Malcolm Smith, National Cancer Institute
Jeffrey Abrams, National Cancer Institute
- 2:00 p.m. **Project 1: The San Francisco Bay Area Adult Glioma Survival Study**
Margaret Wrensch, University of California, San Francisco
- 2:12 p.m. **Project 2: Prognostic Value of Magnetic Resonance Spectroscopic Imaging Parameters for Patients With Glioma**
Susan Chang, University of California, San Francisco
Sarah Nelson, University of California, San Francisco

- 2:24 p.m. **Project 3: Development of Novel Lipidic Nanoparticle Therapeutics for Brain Tumor Treatment**
John Park, University of California, San Francisco
Krys Bankiewicz, University of California, San Francisco
Mitchel Berger, University of California, San Francisco
- 2:36 p.m. **Project 4: Exploiting the P13 Kinase Pathway in Human Glioma Therapy**
David Stokoe, University of California, San Francisco
Daphne Haas-Kogan, University of California, San Francisco
William Weiss, University of California, San Francisco
- 2:48 p.m. **Project 5: Heat Shock Protein Vaccine Development: Glioma Immuno-resistance and PI(3)K/Akt/mTOR Pathway Activation**
Andrew Parsa, University of California, San Francisco
Russell Pieper, University of California, San Francisco
- 3:00 p.m. **Animal Model Core**
C. David James, University of California, San Francisco
- 3:07 p.m. **Tissue Bank Core**
Scott VandenBerg, University of California, San Francisco
- 3:15 p.m. **Overview**
Brian Patrick O'Neill, Mayo Clinic, Rochester
Robert Jenkins, Mayo Clinic, Rochester
- 3:25 p.m. **Dendritic Cell Trial**
Allan Dietz, Mayo Clinic, Rochester
- 3:40 p.m. **Serum Biomarker Trial**
Isobel Scarisbrick, Mayo Clinic, Rochester
- 3:55 p.m. **Viral Gene Therapy "Plus" Trial**
Evanthia Galanis, Mayo Clinic, Rochester

- 4:10 p.m. **Genetic Epidemiology of Glioma**
Ping Yang, Mayo Clinic, Rochester
- 4:30 p.m. **The Cancer Genome Atlas (TCGA) Project Update**
Daniela Gerhard, National Cancer Institute
Joe Gray, Lawrence Berkeley National Laboratory
- 5:00 p.m. **Discussion**
- 5:15 p.m. **Presentation of TGen Effort**
Michael Berens, Translational Genomics Research Institute
- 5:45 p.m. **Discussion**

Breast**Grand Ballroom II-III**

- Chairs:* *Nancy Davidson, Johns Hopkins University*
James Ingle, Mayo Clinic College of Medicine
- NIH Facilitators:* *Barbara Vonderhaar and Shamala Srinivas, National Cancer Institute*
- 2:00 p.m. **Introduction**
Nancy Davidson, Johns Hopkins University
James Ingle, Mayo Clinic College of Medicine
- 2:10 p.m. **Multiplexed In Situ Analysis of Protein Expression (AQUA™) to Predict Breast Cancer Prognosis and Response to Trastuzumab**
David Rimm, Yale University School of Medicine
- 2:20 p.m. **Discussion**
- 2:25 p.m. **QM-MSP, Ki-67, and Cytomorphology of RPFNA Specimens From Women at High Risk for Developing Breast Cancer**
Carol Fabian, University of Kansas
- 2:35 p.m. **Discussion**

- 2:40 p.m. **A Phase II Trial of Neoadjuvant Therapy With Letrozole for Stage 2 and 3 ER+ Breast Cancer in Postmenopausal Women**
Matthew Ellis, Washington University in St. Louis
- 2:50 p.m. **Discussion**
- 2:55 p.m. **Characterization of Gene Expression in Normal Breast of Women Enrolled in a Gonadotropin-Releasing Hormone Agonist (GnRHa)-Based Chemoprevention Regimen**
Michael Press, University of Southern California
- 3:05 p.m. **Discussion**
- 3:10 p.m. **Antigen-Presenting Cell-Targeted hCG β Vaccine for Cancer Therapy**
Michael Morse, Duke University Medical Center
- 3:20 p.m. **Discussion**
- 3:25 p.m. **A Phase I Study of an Autologous GM-CSF-Secreting Cancer Vaccine for Metastatic Breast Cancer**
Karen Anderson, Dana-Farber Cancer Institute
- 3:35 p.m. **Discussion**
- 3:40 p.m. **Early Assessment of Response to Targeted Therapy in Breast Cancer**
Hannah Linden, University of Washington, Seattle
- 3:50 p.m. **Discussion**
- 3:55 p.m. **The *Ella* Binational Breast Cancer Study**
María Elena Martínez, University of Arizona
- 4:05 p.m. **Discussion**
-

GI/Pancreas**Dover A-C**

- Chairs:* Robert Coffey, Vanderbilt University
Gloria Petersen, Mayo Clinic, Rochester
- NIH Facilitators:* Paul Wagner and Heng Xie, National Cancer Institute
- 2:00 p.m. **SPORE Program Update**
Ivan Ding, National Cancer Institute
- 2:10 p.m. **New GI SPORE Overview**
Charles Fuchs, Dana-Farber Cancer Institute
- Advances in Mouse Models of Colonic and Pancreatic Neoplasia: Their Application to Human Disease**
- 2:30 p.m. ***Modeling the Initiation and Progression of Intestinal Cancer***
William Grady, Fred Hutchinson Cancer Research Center
- 3:00 p.m. ***Mutationally Activated K-Ras Exerts Pleiotropic Effects on a Developing Colon Cancer***
Kevin Haigis, Massachusetts General Hospital
- 3:30 p.m. ***Genetic/Nutrient Interactions in Intestinal Cell Maturation and Cancer***
Leonard Augenlicht, Albert Einstein Cancer Center
- 4:00 p.m. **Break**
- 4:15 p.m. ***Identification of Pancreatic Cancer Biomarkers Using Comparative Proteomics***
Nabeel Bardeesy, Harvard Medical School
- 4:45 p.m. ***Direct Xenografting of Pancreatic Cancer Program: A Platform for Drug Screening, Biomarker Discovery, and Individualized Treatment***
Manuel Hidalgo, Johns Hopkins University

- 5:15 p.m. **Molecular Imaging and Drug Discovery in GI Cancer (Network for Translational Research in Optical Imaging)**
Wafik El-Deiry, University of Pennsylvania
- 5:30 p.m. **Marked Efficacy of Difluoromethyl-ornithine Plus Sulindac in Reducing Recurrent Colorectal Adenomas in Patients With Prior Adenomas: Results of a Randomized, Placebo-Controlled Double-Blind Trial**
Frank Meyskens, University of California, Irvine

Head & Neck and Cervical
Laurel C-D

- Chairs:* *Jennifer Grandis, University of Pittsburgh*
T.C. Wu, Johns Hopkins University
- NIH Facilitators:* *Yasaman Shirazi, National Institute of Dental and Craniofacial Research*
H. Nelson Aguila, National Cancer Institute
- 2:00 p.m. **Gene Expression and MicroRNA Analysis of Human Papillomavirus-Associated Cervical and Oral Cancers**
Saleem Khan, University of Pittsburgh
- 2:30 p.m. **Oral HPV Infection and Head and Neck Cancer Risk as It Relates to Genital HPV Infection**
Camille Ragin, University of Pittsburgh
- 2:50 p.m. **HPV Titer, EGFR and p16 Expression, Gender, and Smoking Affect Response to Therapy and Survival in Oropharyngeal Cancer**
Thomas Carey, University of Michigan
- 3:10 p.m. **Circulating HPV16 DNA as Potential Marker of Recurrence in Oropharyngeal Cancer**
Erich Sturgis, University of Texas M.D. Anderson Cancer Center
- 3:30 p.m. **Break**

- 3:50 p.m. **Joe Moakley Leukemia SPORE at University of Texas M.D. Anderson Cancer Center**
Jean-Pierre Issa, University of Texas M.D. Anderson Cancer Center
- 4:05 p.m. **Dana-Farber/Harvard Cancer Center Myeloma SPORE**
Kenneth Anderson, Dana-Farber/Harvard Cancer Center
- 4:20 p.m. **Regulatory T Cells in B Cell Lymphoma**
Stephen Ansell, Mayo Clinic, Rochester
- 4:40 p.m. **Complement in Antibody Therapy of Lymphoma**
Thomas Witzig, Mayo Clinic, Rochester
George Weiner, University of Iowa
- 5:00 p.m. **Epigenetic Work and Trials in Non-Hodgkin's Lymphoma and Hodgkin's Disease**
Mark Kirschbaum, City of Hope
- 5:20 p.m. **CD19-Specific Cells in the Treatment of Low-Grade Lymphoma and Plans for Large Cell and Mantle Cell Lymphomas**
Michael Jensen, City of Hope
- 5:40 p.m. **Immunologic Scars in Hodgkin's Patients**
Richard Ambinder, Johns Hopkins University
- 6:00 p.m. **Nanoparticle-Based Chemotherapy for Lymphoma**
Stephen Forman, City of Hope
-

Kidney**Waterview C-D**

- Chair: Michael Atkins, Dana-Farber/Harvard Cancer Center*
- 2:00 p.m. **Adoptive Immunotherapy for Renal Carcinoma Using Dendritic Cell/Tumor Fusions**
David Avigan, Beth Israel Deaconess Medical Center
- 2:25 p.m. **Combination Therapy With the Akt Inhibitor Perifosine**
James Mier, Beth Israel Deaconess Medical Center
- 2:50 p.m. **Acquired Resistance to VEGF Receptor Blockade: Underlying Mechanism and Therapeutic Options**
S. Nahum Goldberg, Beth Israel Deaconess Medical Center
- 3:15 p.m. **Discovery and Initial Validation of Candidate Biomarkers for Renal Cell Carcinoma**
Othon Iliopoulos, Harvard Medical School
- 3:40 p.m. **Break**
- 4:00 p.m. **Human RCC Short-Term Culture Xenografts in RCC: Development and Potential Application**
Christopher Wood, University of Texas M.D. Anderson Cancer Center
- 4:30 p.m. **Report on the NCI-Sponsored Renal Cancer Biomarkers Workshop**
*Sabina Signoretti, Harvard University
Gennady Bratslavsky, National Cancer Institute*
- 5:00 p.m. **Blood-Based Biomarkers of Angiogenesis: The Role of CECs and Proteins**
John Heymach, University of Texas M.D. Anderson Cancer Center
- 5:30 p.m. **NCI Efforts With Imaging Biomarkers and Interventional Radiology in RCC**
Gary Dorfman, National Cancer Institute

Lung**Essex A-C**

Chairs: Bruce Johnson, Dana-Farber Cancer Institute
Stephen Baylin, Johns Hopkins University

NIH Facilitator: James Jacobson, National Cancer Institute

2:00 p.m. **SPORE Highlights**
Four best abstracts emphasizing new/junior investigators and new areas of research are selected from submitted abstracts.

Proteomic Analyses of Prognosis and Risk

Chairs: John Minna, University of Texas Southwestern Medical Center
Jill Siegfried, University of Pittsburgh

3:00 p.m. **Introduction/Overview**
David Carbone, Vanderbilt University

3:15 p.m. **Proteomic Profiles of Tissue for Risk**
David Beer, University of Michigan

3:35 p.m. **Proteomic Profiles of Tissue and Serum for Risk**
William Bigbee, University of Pittsburgh

3:55 p.m. **Proteomic Profiles of Serum for Risk**
Pierre Massion, Vanderbilt University

4:15 p.m. **Proteomic Profiles of Serum for Risk**
Mark Duncan, University of Colorado

4:30 p.m. **Break**

4:45 p.m. **Proteomic Profiles of Serum for Drug Sensitivity Prediction**
Heinrich Röder, Biodesix, Inc.

5:05 p.m. **Proteomic Profiles of Serum for Drug Sensitivity Prediction**
David Carbone, Vanderbilt University

5:20 p.m. **Lung Cancer Biomarkers Group**
William Bigbee, University of Pittsburgh

5:40 p.m. **Discussion**

Ovarian**Kent A-C**

-
- Chair:* *Nicole Urban, Fred Hutchinson Cancer Research Center*
- NIH Facilitator:* *Padma Maruvada, National Cancer Institute*
- 2:00 p.m. **Introduction**
Nicole Urban, Fred Hutchinson Cancer Research Center
- 2:15 p.m. **Risk Modeling (Potential InterSPORE Collaboration on Prevention)**
Garnet Anderson, Fred Hutchinson Cancer Research Center
- 2:45 p.m. **Risk Factors for Ovarian Cancer (Potential InterSPORE Collaboration on Prevention)**
Daniel Cramer, Harvard Medical School
- 3:15 p.m. **The Cancer Genome Atlas (TCGA): NCI Initiative**
Daniela Gerhard, National Cancer Institute
- 3:45 p.m. **Validation of Serum Markers for Breast Cancer: SPORE Collaboration (Avon)**
Nicole Urban, Fred Hutchinson Cancer Research Center
- 4:15 p.m. **Validation of Serum Markers for Ovarian Cancer: SPORE Collaboration Update (PLCO/EDRN)**
Patricia Hartge, National Cancer Institute
Christine Berg, National Cancer Institute
- 4:45 p.m. **Therapeutics/Intraperitoneal Avastin Study: SPORE Collaboration Update (GOG/NCI)**
Carolyn Krasner, Dana-Farber/Harvard Cancer Center
Michael Birrer, National Cancer Institute
- 5:15 p.m. **Discussion**
-

Prostate**Grand Ballroom VIII-IX**

*Chairs: William Nelson, Johns Hopkins University
Peter Scardino, Memorial Sloan-Kettering
Cancer Center*

*NIH Facilitators: Alison Martin, William Dahut, Suresh
Mohla, National Cancer Institute*

2:00 p.m. Welcome
*William Nelson, Johns Hopkins University
Peter Scardino, Memorial Sloan-Kettering
Cancer Center*

NCI Presentation
*Jorge Gomez, National Cancer Institute
Andrew Hruszkewycz, National Cancer
Institute*

**2:15 p.m. Charge to the Prostate SPORE
Working Groups**
*William Nelson, Johns Hopkins University
Peter Scardino, Memorial Sloan-Kettering
Cancer Center*

**2:20 p.m. First Prostate SPORE Working Group
Sessions**

***Genetic Studies/Population Sciences
Working Group***
*Kathleen Cooney, University of Michigan
Janet Stanford, Fred Hutchinson Cancer
Research Center
William Catalona, Northwestern
University*

Androgen Receptor Working Group
*Donald Tindall, Mayo Clinic, Rochester
Steven Balk, Harvard University*

Signal Transduction Working Group
*Celestia Higano, University of
Washington, Seattle
Timothy Thompson, Baylor University*

Immunotherapy
*Eric Small, University of California, San
Francisco
Charles Drake, Johns Hopkins University*

- 3:15 p.m. **Clinical Trials in the Prostate SPOREs**
Howard Scher, Memorial Sloan-Kettering Cancer Center
Philip Kantoff, Dana-Farber Cancer Institute
Christopher Logothetis, University of Texas M.D. Anderson Cancer Center
- 3:45 p.m. **Gene Fusions**
Arul Chinnaiyan, University of Michigan
- 4:15 p.m. **Molecular Epidemiology and the 8q Gene Locus**
Presentations and Panel Discussion
Janet Stanford, Fred Hutchinson Cancer Research Center
Elaine Ostrander, National Human Genome Research Institute
Matthew Freedman, Dana-Farber Cancer Institute
Robert Jenkins, Mayo Clinic, Rochester
William Isaacs, Johns Hopkins University
- 5:00 p.m. **Summary Presentations of Working Group Recommendations and Plans**
- Chairs:* *Matthew Freedman, Dana-Farber Cancer Institute*
Robert Jenkins, Mayo Clinic, Rochester
- 5:00 p.m. ***Genetic Studies/Population Sciences Working Group***
Kathleen Cooney, University of Michigan
Janet Stanford, Fred Hutchinson Cancer Research Center
William Catalona, Northwestern University
- 5:15 p.m. ***Androgen Receptor Working Group***
Donald Tindall, Mayo Clinic, Rochester
Steven Balk, Harvard University
- 5:30 p.m. ***Signal Transduction Working Group***
Celestia Higano, University of Washington, Seattle
Timothy Thompson, Baylor University
- 5:45 p.m. ***Immunotherapy Working Group***
Eric Small, University of California, San Francisco
Charles Drake, Johns Hopkins University

Skin**Grand Ballroom I**

Chair: Ruth Halaban, Yale University

NIH Facilitators: Magdalena Thurin and Devi Vembu, National Cancer Institute

Melanoma Bioinformation Grid (MelaGRID)

*Moderators: Michael Krauthammer, Yale University
Jeffrey Gershenwald, University of Texas
M.D. Anderson Cancer Center*

2:00 p.m. **Introduction to MelaGRID**
*Michael Krauthammer, Yale University
David Tuck, Yale University*

2:20 p.m. **CGH and SNP in Melanoma**
*Katherine Nathanson, The Wistar
Institute/University of Pennsylvania*

2:50 p.m. **Multimodality "Omic" Analysis of Melanoma**
*Jeffrey Gershenwald, University of Texas
M.D. Anderson Cancer Center*

3:30 p.m. **Genes Involved in Metastasis**
Lynda Chin, Harvard University

3:45 p.m. **Break**

**Biomarker Validation for Melanoma/
Technology**

*Moderators: Lyn Duncan, Harvard University
David Rimm, Yale University
Victor Prieto, University of Texas M.D.
Anderson Cancer Center*

4:00 p.m. **Update on SPORE Melanoma Biomarker Validation Effort**
Lyn Duncan, Harvard University

4:15 p.m. **Technology for Melanoma Biomarkers**

Fluorescence-Based Assessment of Protein Expression in Melanoma (AQUA)
David Rimm, Yale University

Developing New Imaging Technology for
Dermatopathology Diagnosis
*David Elder, The Wistar Institute/
University of Pennsylvania*

4:55 p.m. ***Progress Update From M.D. Anderson
Cancer Center***

Update on the Prognostic Significance
of iNOS and NT Expression in Primary
Melanoma
*Victor Prieto, University of Texas M.D.
Anderson Cancer Center*

Immunogenetic Polymorphisms as
Melanoma Prognostic Markers: HLA and
Beyond
*Jeffrey Lee, University of Texas M.D.
Anderson Cancer Center*

5:30 p.m. ***Panel: How Do We Advance
Biomarkers From Publications to
Clinical Use?***

Panel *David Rimm, Yale University*
Members: *Lyn Duncan, Harvard University*
*Victor Prieto, University of Texas M.D.
Anderson Cancer Center*
*David Elder, The Wistar Institute/
University of Pennsylvania*

**Avon-Foundation for the NIH (FNIH) -
NCI Progress for Patients (PFP) Blue
Ribbon Panel (*closed meeting*)**

6:00 p.m. - 7:00 p.m.

Boardroom

**"Opportunities for Networking and
Collaboration" Reception (*prepaid fee
event*)**

6:00 p.m. - 8:00 p.m.

Harborside Ballroom Foyer

This forum is designed to encourage and enhance
communication through interaction and discussion
across organ site programs and the many diverse
constituents in the cancer research enterprise.

**NCI Center for Bioinformatics
Demonstration of Translational Tools**

6:30 p.m. - 8:00 p.m.

Salons V-VI

**Viruses in Cancer Treatment and
Prevention: SPORE Interest Group**

7:00 p.m. - 9:00 p.m.

Dover A-B

**Risk Models for Prediction of Lung
Cancer and Chemoprevention**

7:00 p.m. - 9:00 p.m.

Salons VIII-IX

**Preliminary Discussion With *Ella*
Study Scientific Advisory Board
(closed meeting)**

7:00 p.m. - 9:00 p.m.

Boardroom

I-SPY Meeting (closed meeting)

7:00 p.m. - 10:00 p.m.

Waterview C-D

**Lung Cancer Biomarkers Group
(closed meeting)**

7:00 p.m. - 10:00 p.m.

Galena

**Prostate Cancer Clinical Trials Working
Group**

8:00 p.m. - 10:00 p.m.

Waterview A-B

Breakfast (*on your own*)

7:00 a.m. - 8:00 a.m.

Inter-Prostate SPORE Biomarker Study (IPBS) Meeting

7:00 a.m. - 8:00 a.m.

Heron

Prostate SPORE Directors' Meeting (*closed meeting*)

7:00 a.m. - 8:00 a.m.

Boardroom

2007 GI SPORE Clinical Trial Committee Meeting (*closed meeting*)

7:00 a.m. - 8:00 a.m.

Galena

Registration

7:00 a.m. - 7:00 p.m.

Grand Registration Desk

NCI Center for Bioinformatics Booth Learning Center

8:00 a.m. - 7:00 p.m.

Grand Registration Foyer

Plenary Session II

8:00 a.m. - 10:00 a.m.

Grand Ballroom V-VI

This session will present highlights of findings from joint DHHS and NCI initiatives targeting research in groundbreaking areas. The strategy underpinning these initiatives and the projected outcomes will be discussed, and experts will give scientific presentations about exciting new prospects resulting from collaborations across the biomedical research enterprise.

8:00 a.m. **Translational Research Opportunities Stemming From the Cancer Genome Atlas (TCGA) Project**
Joe Gray, Lawrence Berkeley National Laboratory

8:20 a.m. **Clinical Proteomics: Progress and Barriers**
Daniel Liebler, Vanderbilt University

- 8:40 a.m. **Opportunities for Biomarker Qualification in Oncology**
Gary Kelloff, National Cancer Institute
Janet Woodcock, U.S. Food and Drug Administration
- 9:10 a.m. **Breast Cancer Stem Cells: Clinical Implications**
Max Wicha, University of Michigan
- 9:30 a.m. **Integration of Centers for Cancer Nanotechnology Excellence and the SPORE Program: Potential for Synergies**
David Agus, Cold Spring Harbor Laboratory
- 9:45 a.m. **Presurgical and Neoadjuvant Trials: Role in Clinical Development of New Targeted Therapies and Combinations**
Carlos Arteaga, Vanderbilt University

Models for Collaborations and Partnerships

10:00 a.m. - 12 noon

Grand Ballroom V-VI

The objective of this session is to discuss different collaboration and partnership models that will advance cancer research and improve cancer patient management as well as health outcomes of individuals at risk for cancer. Participants will include for-profit and non-profit organizations, academic institutions, Cancer Centers, SPOREs, FDA, NIH, and other appropriate DHHS regulatory offices including the Foundation for the NIH, NCI Ethics Office, NIH Office of Legal Council, and NCI Office of Technology Transfer. The agenda will address the following questions: (1) How will intellectual property issues be managed? (2) Who will own the data? (3) How will the data be managed? (4) How will cosponsorship opportunities be achieved? (5) How will scientific projects be selected and prioritized? Existing models and barriers related to collaborations and partnerships will be discussed, specifically, the limitations surrounding cosponsoring clinical research studies. The anticipated outcome is to develop a strategic plan for identifying barriers to overcoming logistical, funding, intellectual property, and data-sharing issues.

Chair: Nancy Davidson, Johns Hopkins School of Medicine

10:00 a.m. Introduction and Objectives of the Session
Nancy Davidson, Johns Hopkins School of Medicine

10:05 a.m. NIH and Public-Private Partnerships
Barbara Mittleman, National Institutes of Health

10:25 a.m. Public-Private Partnerships: The Good, The Bad, and The Ugly
Gregory Curt, AstraZeneca

10:45 a.m. The SPORE as a Model for Enhancing Collaborative Translational Research
Kenneth Anderson, Dana-Farber/Harvard Cancer Center

11:05 a.m. Panel Discussion and Q&A

Lunch Break (*on your own*)

12 noon - 1:30 p.m.

SPORE Directors' and Patient Advocates' Working Luncheon (*invitation only*)

12 noon - 2:00 p.m.

Grand Ballroom II-III

Logistics/Coordination Meeting of the Avon-FNIH-NCI PFP *Ella* Binational Breast Cancer Study (*closed meeting*)

12 noon - 2:00 p.m.

Boardroom

Concurrent Poster Discussion Sessions I

1:30 p.m. - 3:30 p.m.

Investigators will be selected by the Planning Committee to present their poster topics in more detail for further discussion of groundbreaking translational research. Each session will have up to eight presentations under each poster topic. These talks reflect the best efforts of investigators in the SPORE Program.

Biomarkers I

Grand Ballroom V

Cancer biomarkers discovery, development, and translation are major components of the SPORE Program. Correlative biomarker data are key to the processes of strong scientific inference needed for translational research, and biomarkers may become useful tests for risk assessment, early detection, diagnosis, prognosis, prediction to therapy, or preventive measures. The process of biomarker development is based on pre-analytical considerations and analytic and clinical validation. The following session will be an update on recent advances and a platform for discussion among experts.

Chairs: Gloria Petersen, Mayo Clinic, Rochester
Angelo De Marzo, Johns Hopkins University

NIH Facilitator: Yasaman Shirazi, National Institute of Dental and Craniofacial Research

1:30 p.m. **065: A Tissue Biomarker Panel That Predicts Which Men With a Rising Prostate-Specific Antigen Postdefinitive Prostate Cancer Therapy Will Have Systemic Progression**
Robert Jenkins, Mayo Clinic, Rochester

1:45 p.m. **072: Multiplexed In Situ Analysis of Protein Expression (AQUA™) To Predict Breast Cancer Prognosis and Response to Trastuzumab**
David Rimm, Yale University

- 2:00 p.m. **128: Genomewide and Promoter-Specific Analyses Identify Novel Targets of Aberrant DNA Methylation in Adult Acute Lymphocytic Leukemias**
Shao-Qing Kuang, University of Texas M.D. Anderson Cancer Center
- 2:15 p.m. **074: Validation and Streamlining of Ovarian Cancer Prognostic Profiles With a Customized Genechip**
Dimitrios Spentzos, Beth Israel Deaconess Medical Center
- 2:30 p.m. **042: Clinical Classification of BRCA1 and BRCA2 Variants of Uncertain Significance**
Fergus Couch, Mayo Clinic, Rochester
- 2:45 p.m. **073: Identification of microRNAs That Modulate Sensitivity to Paclitaxel of Non-Small Cell Lung Cancer**
Alexander Pertsemlidis, University of Texas Southwestern Medical Center
- 3:00 p.m. **114: Specific Chromosomal Abnormalities in Primary Central Nervous System Lymphoma Differ From Those of Systemic Diffuse Large B Cell Lymphoma, Suggesting a Distinct Pathogenesis**
Brian Patrick O'Neill, Mayo Clinic, Rochester
- 3:15 p.m. **159: Heterogeneity of Breast Cancer Metastases: A Rapid Autopsy Study Using Matched Primary-Metastases Tissue Microarrays**
Pedram Argani, Johns Hopkins University
-

Molecular Targets and Novel Therapies I**Grand Ballroom VI**

Development of targeted therapy is one of the fastest growing fields in cancer treatment and prevention. This session will provide an opportunity to discuss breakthroughs, solve problems, and share information on cancer treatment and up-to-date correlative assays to predict treatment outcomes.

Chairs: James Ingle, Mayo Clinic, Rochester
Mace Rothenberg, Vanderbilt University

NIH Facilitator: Roy Wu, National Cancer Institute

1:30 p.m. **237: Targeting Transforming Growth Factor β Receptor as a Therapeutic Approach to Suppressing Pancreatic Cancer Metastasis**
Paul Chiao, University of Texas M.D. Anderson Cancer Center

1:45 p.m. **249: Phase I Evaluation of Therapeutic, E7-Targeted DNA Vaccination in Women With HPV16+ High-Grade Cervical Dysplasia (CIN2/3)**
Cornelia Trimble, Johns Hopkins University

2:00 p.m. **239: Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency**
Dihua Yu, University of Texas M.D. Anderson Cancer Center

2:15 p.m. **273: The Dual Tyrosine Kinase Inhibitor, Lapatinib, Prevents ER-Negative Breast Cancer by Suppressing the Development of Premalignant Lesions**
Powel Brown, Baylor College of Medicine

2:30 p.m. **210: Stimulation of Antitumor Immunity Using Dendritic Cell/Tumor Fusions and Anti-CD3/CD28**
Jacalyn Rosenblatt, Dana-Farber/Harvard Cancer Institute

- 2:45 p.m. **232: Interleukin-13 Displaying Oncolytic Measles Virus Strains Have Tumor-Specific Activity Against Gliomas With an Improved Therapeutic Index**
Evanthia Galanis, Mayo Clinic, Rochester
- 3:00 p.m. **165: Arsenic Trioxide Enhances the Antitumor Effects of Radiation Treatment While Protecting the Bone**
Pawan Kumar, University of Michigan
- 3:15 p.m. **252: Restricted, Uniform, and Constitutive Cell Surface Expression of Receptor Tyrosine Kinase-Like Orphan Receptor 1 in Chronic Lymphocytic Leukemia**
Christoph Rader, National Cancer Institute
-

New Technologies and Methodologies in Translational Research I **Grand Ballroom VIII-IX**

This session encompasses a wide expanse of technologies with potential application not only in cancer therapy, but also in prediction, diagnosis, risk assessment, and prevention of cancer. Bioinformatics is rapidly advancing toward developing powerful tools for data acquisition, analysis, modeling, and data mining through innovations in software architecture and new algorithms. We look to nanotechnology solutions for improvements in cancer prevention, detection, and therapy. Proteomics is evolving technologies to identify proteins and peptides in complex specimen mixtures that are used in prediction, prevention, and treatment at an individual level. Genomics endeavors to understand the molecular basis of cancer through the development and application of high-resolution genome analysis technologies. Genomic technologies are augmented by computational and informatics tools that offer Web-based resources for characterization of cancer. Metabolomics is a new field advancing studies to assess the metabolic networks pertinent to pathophysiology. These sessions offer a multi-disciplinary discussion forum for enhancing translational research and developing interinstitutional networks.

Chairs: *Russell Pieper, University of California, San Francisco*
Daniel Chan, University of Colorado Cancer Center

NIH Facilitator: *Shamala Srinivas, National Cancer Institute*

1:30 p.m. **068: Comparison of Sample Preparation and Solubilization Techniques for Shotgun Proteomic Analysis of Laser Capture Microdissected Cells From Human Breast Tumors**
Melinda Sanders, Vanderbilt University

1:45 p.m. **092: Automated, Whole-Slide-Based Multiplexed Molecular Marker Assessment in Formalin-Fixed, Paraffin-Embedded Tissues**
Richard Levenson, CRI, Inc.

- 2:00 p.m. **058: Genomewide Approach to Identifying Genetic Variants That Contribute to Chemotherapy-Induced Cytotoxicity**
Eileen Dolan, University of Chicago
- 2:15 p.m. **171: Establishment and Molecular Characterization of Mouse Xenografts of Organ-Confined Human Prostate Tumors**
Massimo Loda, Dana-Farber/Harvard Cancer Center
- 2:30 p.m. **147: High Cancer-Specific Expression of an Overexpressed Biomarker Is Attributable to an Upstream Enhancer**
Tomas Hucl, Johns Hopkins University
- 2:45 p.m. **006: Urine Cytology for Prostate Cancer Detection: Immunocytostains of Urine Sediment in the Era of New Prostate-Specific Biomarkers**
Kazutoshi Fujita, Johns Hopkins University
- 3:00 p.m. **020: Multislice High Spectral and Spatial Resolution Magnetic Resonance Imaging of Entire Human Breast**
Gregory Karczmar, University of Chicago
- 3:15 p.m. **094: Arterial Spin Labeling MR Perfusion Provides Radiologic-Pathologic Correlation for Monitoring Responses to Antiangiogenic Therapy in Renal Cell Cancer Animal Models**
S. Nahum Goldberg, Dana-Farber/Harvard Cancer Center
-

Budget Meeting of the *Ella* Study Principal Investigators with NCI and Avon Foundation (*closed meeting*)

2:00 p.m. - 2:30 p.m.

Boardroom

Concurrent Poster Discussion Sessions II

3:30 p.m. - 5:30 p.m.

Investigators will be selected by the Planning Committee to present their poster topics in more detail for further discussion of groundbreaking translational research. Each session will have up to eight presentations under each poster topic. These talks reflect the best efforts of investigators in the SPORE Program.

Biomarkers II

Grand Ballroom V

Cancer biomarkers discovery, development, and translation are major components of the SPORE Program. Correlative biomarker data are key to the processes of strong scientific inference needed for translational research, and biomarkers may become useful tests for risk assessment, early detection, diagnosis, prognosis, prediction to therapy, or preventive measures. The process of biomarker development is based on pre-analytical considerations and analytic and clinical validation. The following session will be an update on recent advances and a platform for discussion among experts.

Chairs: Gordon Mills, University of Texas M.D. Anderson Cancer Center
William Bigbee, University of Pittsburgh

NIH Facilitator: Paul Wagner, National Cancer Institute

3:30 p.m. **053: New-Onset Diabetes Precedes Onset of Symptoms and Diagnosis of Pancreatic Cancer: Implications for Early Diagnosis of Pancreatic Cancer**
Suresh Chari, Mayo Clinic, Rochester

3:45 p.m. **112: Protein Expression Profiling To Determine Potential Markers of Therapeutic Response in Breast Cancer**
Jennifer Pietenpol, Vanderbilt University

- 4:00 p.m. **121: Functional Proteomic Profiling of AML Predicts Response, Relapse, and Clinical Outcome**
Steven Kornblau, University of Texas M.D. Anderson Cancer Center
- 4:15 p.m. **016: Distinct Classes of Chromosomal Rearrangements Create Oncogenic ETS Gene Fusions in Prostate Cancer**
Arul Chinnaiyan, University of Michigan
- 4:30 p.m. **087: PSA Dynamics Do Not Improve the Predictive Accuracy of a Single Protein-Specific Antigen Measurement in Either Long-Term Prediction of Prostate Cancer Diagnosis or Outcome From Radical Prostatectomy**
Hans Lilja, Memorial Sloan-Kettering Cancer Center
- 4:45 p.m. **110: Disseminated Tumor Cells in Prostate Cancer: Implications for Systemic Progression and Tumor Dormancy**
Todd Morgan, University of Washington, Seattle, and Fred Hutchinson Cancer Research Center
- 5:00 p.m. **084: Evidence From Transgenic Mouse Models: Preclinical Studies and In Silico Data Analysis Point to a Role for HOXB7 in Tamoxifen Resistance and Poor Disease Outcome**
Saraswati Sukumar, Johns Hopkins University
- 5:15 p.m. **082: A Systems Approach to Marker-Guided Therapy**
Joe Gray, Lawrence Berkeley National Laboratory
-

Molecular Targets and Novel Therapies II**Grand Ballroom VI**

Development of targeted therapy is one of the fastest growing fields in cancer treatment and prevention. This session will provide an opportunity to discuss breakthroughs, solve problems, and share information on cancer treatment and up-to-date correlative assays to predict treatment outcomes.

Chairs: Paul Bunn, University of Colorado Cancer Center

Daniel Cramer, Dana-Farber/Harvard Cancer Center

NIH Facilitator: Barbara Vonderhaar, National Cancer Institute

3:30 p.m. **211: Systemic Therapy With Tumor Suppressor FUS1-Nanoparticles for Stage 4 Lung Cancer**
Jack Roth, University of Texas M.D. Anderson Cancer Center

3:45 p.m. **139: Identification of Melanoma Cells With Resistance to BRAF and MEK Inhibitors**
Keiran Smalley, The Wistar Institute/ University of Pennsylvania

4:00 p.m. **274: Activation of LMP1- and LMP2-Specific T Cells for the Immunotherapy of EBV-Positive Lymphomas With an Adenoviral Vector Encoding Full-Length LMP1 and LMP2**
Stephen Gottschalk, Baylor College of Medicine

4:15 p.m. **187: Design and Evaluation of Novel Small-Molecule Inhibitors of the MDM2-p53 Interaction as a New Anticancer Therapy**
Shaomeng Wang, University of Michigan

- 4:30 p.m. **140: Anti-CS1 Humanized Monoclonal Antibody HuLuc63 Inhibits Myeloma Cell Adhesion and Growth in the Bone Marrow Milieu and Targets the Cells for Killing via Antibody-Dependent Cellular Cytotoxicity**
Yu-Tzu Tai, Dana-Farber/Harvard Cancer Center
- 4:45 p.m. **238: Dysfunctional KEAP1–NRF2 Interaction in Non-Small Cell Lung Cancer as a Critical Factor for Chemoresistance**
Shyam Biswal, Johns Hopkins University
- 5:00 p.m. **203: Bim Mediates Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers With Activating EGFR Mutations and Its Upregulation Is Attenuated by Secondary Resistant Mutations, T790M and a Novel L747S**
Daniel Costa, Dana-Farber/Harvard Cancer Center
- 5:15 p.m. **037: HRQOL and Satisfaction With Cancer Treatment Outcome From the Perspective of Early-Stage Prostate Cancer Patients and Their Spouse/ Partners: Results From a Prospective, Multicenter Study**
Martin Sanda, Dana-Farber/Harvard Cancer Center
-

New Technologies and Methodologies in Translational Research II **Grand Ballroom VIII-IX**

This session encompasses a wide expanse of technologies with potential application not only in cancer therapy, but also in prediction, diagnosis, risk assessment, and prevention of cancer. Bioinformatics is rapidly advancing toward developing powerful tools for data acquisition, analysis, modeling, and data mining through innovations in software architecture and new algorithms. We look to nanotechnology solutions for improvements in cancer prevention, detection, and therapy. Proteomics is evolving technologies to identify proteins and peptides in complex specimen mixtures that are used in prediction, prevention, and treatment at an individual level. Genomics endeavors to understand the molecular basis of cancer through the development and application of high-resolution genome analysis technologies. Genomic technologies are augmented by computational and informatics tools that offer Web-based resources for characterization of cancer. Metabolomics is a new field advancing studies to assess the metabolic networks pertinent to pathophysiology. These sessions offer a multi-disciplinary discussion forum for enhancing translational research and developing interinstitutional networks.

Chairs: *Colin Collins, University of California, San Francisco*
Robert Jenkins, Mayo Clinic, Rochester

NIH Facilitator: *Keyvan Farahani, National Cancer Institute*

3:30 p.m. **009: Noninvasive Imaging Metrics To Profile Treatment Response in Models of Colorectal Cancer**
H. Charles Manning, Vanderbilt University

3:45 p.m. **077: Adenovirus-Mediated Gene Expression Imaging To Directly Detect Sentinel Lymph Node Metastasis of Prostate Cancer**
Lily Wu, University of California, Los Angeles

- 4:00 p.m. **113: Dual-Labeled Trastuzumab-Based Imaging Agent for the Detection of HER2 Overexpression in Breast Cancer**
Eva Sevick, Baylor College of Medicine
- 4:15 p.m. **132: Restoration of E-Cadherin in Colon Cancer Cells: Identification by High-Throughput Screening**
A. Scott Pearson, Vanderbilt University
- 4:30 p.m. **263: Development and In Vitro Validation of Anti-Mesothelin Biobodies That Prevent CA125/Mesothelin-Dependent Cell Attachment**
Nathalie Scholler, Fred Hutchinson Cancer Research Center
- 4:45 p.m. **231: Chemical Genetics Approach for Dissecting Wnt Signal Transduction Using a Novel Biochemical Approach Based on Theoretical Considerations**
Ethan Lee, Vanderbilt University School of Medicine
- 5:00 p.m. **030: BioMark™ System: Integrated Fluidic Circuits Enable the Use of Real-Time qPCR for Cancer Gene Expression Panels, Drug Resistance Monitoring, and Circulating Tumor Cell Detection**
Marc Unger, Fluidigm Corporation
- 5:15 p.m. **262: Combination of V β Spectratyping/CD107 Degranulation Assays To Monitor Directly Ex Vivo Antitransgene T Cell Immune Responses in Lymphoma Patients Receiving Adoptive Immunotherapy**
Michael Kalos, Beckman Research Institute at City of Hope
-

Poster Session and "Meet the Author" Buffet Dinner (*prepaid fee event*)

5:30 p.m. - 8:30 p.m. Harborside Ballroom Foyer

Treatment (Therapy, Prevention, and Chemoprevention), Diagnosis, Prognosis, Prediction, Screening, Risk Assessment, Early Detection

This session will be an opportunity for investigators, industry representatives, patient advocates, cancer research advocates, and NIH staff to share research results in an interactive forum.

Lung SPORE Biospecimen and Informatics

6:00 p.m. - 8:00 p.m. Falkland

Translational Breast Cancer Research Consortium (*closed meeting*)

6:00 p.m. - 10:30 p.m. Dover A-C

Head & Neck/Lung SPOREs Joint Meeting (*closed meeting*)

7:00 p.m. - 9:00 p.m. Waterview Ballroom

Poster Take-down

8:30 p.m. Harborside Ballroom

Breakfast (*on your own*)**7:00 a.m. - 8:00 a.m.****Registration****7:00 a.m. - 12 noon** **Grand Registration Desk****Organ Site Breakout Sessions II****8:00 a.m. - 12 noon**

These breakout sessions will discuss (1) recent scientific advances, (2) opportunities and technologies that could advance the field, (3) collaborations with SPORE or NCI programs and networks, and (4) infrastructure needed to support InterSPORE collaborations, and (5) planned future activities.

Bladder**Waterview A-B**

Chair: *Colin Dinney, University of Texas M.D. Anderson Cancer Center*

NIH Facilitator: *Gary Kelloff, National Cancer Institute*

8:00 a.m. **Introduction**
Colin Dinney, University of Texas M.D. Anderson Cancer Center

8:15 a.m. **RB94 Gene Therapy**
William Benedict, University of Texas M.D. Anderson Cancer Center

8:45 a.m. **Discussion**

8:55 a.m. **Proteomics**
Bogdan Czerniak, University of Texas M.D. Anderson Cancer Center

9:25 a.m. **Discussion**

9:35 a.m. **Break**

9:50 a.m. **Molecular Progression and Models**
Carlos Cordon-Cardo, Columbia University

10:20 a.m. **Discussion**

10:30 a.m. **FGF Receptor 3: Potential Target for Urothelial Cancer**
Colin Dinney, University of Texas M.D. Anderson Cancer Center
David McConkey, University of Texas M.D. Anderson Cancer Center

11:00 a.m. **Discussion**

11:10 a.m. **Predicting Response to BCG Therapy**
Xifeng Wu, University of Texas M.D. Anderson Cancer Center

11:40 a.m. **Discussion**

Brain

Laurel A-B

Chair: Mitchel Berger, University of California, San Francisco

NIH Facilitators: Jane Fountain, National Institute of Neurological Disorders and Stroke
Malcolm Smith and Jeffrey Abrams, National Cancer Institute

8:00 a.m. **Inhibition of Glioma Angiogenesis With Kringle 5**
Candece Gladson, University of Alabama at Birmingham

8:12 a.m. **Discussion**

8:15 a.m. **Optimized Chimeric HSV for Glioma Therapy**
Kevin Cassady, University of Alabama at Birmingham

8:27 a.m. **Discussion**

8:30 a.m. **Death Receptor Antibody Therapy for Anaplastic Gliomas**
Donald Buchsbaum, University of Alabama at Birmingham
John Fiveash, University of Alabama at Birmingham

8:42 a.m. **Discussion**

8:45 a.m. **Ex Vivo Expanded Gamma-Delta T Cells for Immunotherapy of Anaplastic Gliomas**
Lawrence Lamb, University of Alabama at Birmingham

8:57 a.m. **Discussion**

- 9:00 a.m. **Updates on Two Phase I SPORE Clinical Trials (ABT410 Antiangiogenesis Peptide and Oncolytic G207-HSV Plus Radiation)**
L. Burt Nabors III, University of Alabama at Birmingham
James Markert, University of Alabama at Birmingham
- 9:15 a.m. **Project 1: Rational Development of GSTP1-Targeted Antiglioma Therapeutics**
Francis Ali-Osman, Duke University
- 9:25 a.m. **Project 2: Temodar Resistance in Central Nervous System Tumors**
Henry Friedman, Duke University
- 9:35 a.m. **Project 3: Enhancing CMV-Specific Antitumor Immune Responses in Malignant Astrocytomas**
John Sampson, Duke University
- 9:45 a.m. **Project 4: Genetic/Animal Neurocarcinogen Risks and Outcomes for Brain Tumors**
Francis Ali-Osman, Duke University
Faith Davis, University of Illinois, Chicago
- 10:05 a.m. **Overview: Duke SPORE Career Development and Developmental Research Programs**
Darell Bigner, Duke University
- 10:10 a.m. **Measurement of Interobserver Variability in Tumor Size Measurements Using a Novel Permeability Imaging Technique**
James Provenzale, Duke University
- 10:20 a.m. **Discussion**
- 10:30 a.m. **Discussion of TCGA Presentation, and Draft of Brain SPORE Interaction Document**
Mitchel Berger, University of California, San Francisco
Darell Bigner, Duke University
- 11:15 a.m. **Presentation of InterSPORE Clinical Protocols and Prioritization Results**
Michael Prados, University of California, San Francisco

Breast**Grand Ballroom II-III**

- Chairs:* Nancy Davidson, Johns Hopkins University
James Ingle, Mayo Clinic, Rochester
- NIH Facilitators:* Barbara Vonderhaar and Shamala Srinivas, National Cancer Institute
- 8:00 a.m. **Introduction**
Nancy Davidson, Johns Hopkins University
James Ingle, Mayo Clinic, Rochester
- 8:10 a.m. **Genetics of Breast Cancer in Spanish Women**
Pedro Pérez Segura, Hospital Clinico San Carlos de Madrid
- 8:20 a.m. **Discussion**
- 8:25 a.m. **TBCRC 001: EGFR Inhibition With Cetuximab in Metastatic Triple Negative (Basal-Like) Breast Cancer**
Lisa A. Carey, University of North Carolina
- 8:35 a.m. **Discussion**
- 8:40 a.m. **A Phase II Trial of Letrozole Plus Erlotinib in Postmenopausal Women With Hormone-Sensitive Metastatic Breast Cancer: Preliminary Results of Toxicities and Correlative Studies**
Ingrid A. Mayer, Vanderbilt-Ingram Cancer Center
- 8:50 a.m. **Discussion**
- 8:55 a.m. **In Vitro and In Vivo Chemotherapy Sensitivity of Human Basal-Like Tumors**
Charles Perou, University of North Carolina
- 9:05 a.m. **Discussion**

- 9:10 a.m. **Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency**
Dihua Yu, University of Texas M.D. Anderson Cancer Center
- 9:20 a.m. **Discussion**
- 9:25 a.m. **Interference of the HER2 Extracellular Domain at Subdomains I and III Interaction Promotes Growth Advantage and Modulates Hormonal Response**
Ruth Lupu, Lurie Comprehensive Cancer Center
- The Angiogenic Factor Cyr61: $\alpha_6\beta_1$ Integrin and Estrogen Receptor Connection in the Control of Hormonal Response and the Antiestrogen Resistance in Breast Cancer**
Ruth Lupu, Lurie Comprehensive Cancer Center
- 9:45 a.m. **Discussion**
- 9:55 a.m. **General Discussion**

GI/Pancreas**Dover A-C**

Chairs: *Gloria Petersen, Mayo Clinic, Rochester*
Robert Coffey, Vanderbilt University

NIH
Facilitators: *Paul Wagner and Heng Xie, National Cancer Institute*

8:00 a.m. **NCI Extramural Programs Update: EDRN-SPORE Collaborative Projects**
Paul Wagner, National Cancer Institute
Heng Xie, National Cancer Institute

8:20 a.m. **Quantitative Issues in Biomarker Development**
Bonnie LaFleur, Vanderbilt University

8:50 a.m. **Genetic Linkage of Familial Pancreatic Cancer**
Gloria Petersen, Mayo Clinic, Rochester

- 9:10 a.m. **Genomic Analyses of Colorectal Cancer**
Victor Velculescu, Johns Hopkins University
- 9:45 a.m. **Break**
- Spotlight on SPORE Career Development Awardees**
- 10:00 a.m. *Barrett's Esophagus and Oxidative Stress: The Role of Gastric Acid and Bile Acids*
Katerina Dvorak, University of Arizona
- 10:20 a.m. *Rapid Autopsy Genetic Study*
Christine Iacobuzio, Johns Hopkins University
- 10:40 a.m. *HTS for Wnt Targets in Colorectal Cancer*
Ethan Lee, Vanderbilt University
- 11:00 a.m. *Hedgehog Signaling and EGFR Pathway in Pancreatic Cancer*
Martin Fernandez-Zapico, Mayo Clinic, Rochester
- 11:20 a.m. *Identifying Novel Targets and Pathways in Pancreatic Tumorigenesis and Metastasis*
Jen Jen Yeh, University of North Carolina
- 11:40 a.m. *Scr Kinase in Pancreatic Metastases and Scr as a Target for Therapy*
Gary Gallick, University of Texas M.D. Anderson Cancer Center
-

Head & Neck and Cervical**Laurel C-D**

Chairs: Jennifer Grandis, University of Pittsburgh
T.-C. Wu, Johns Hopkins University

NIH Facilitators: Yasaman Shirazi, National Institute of Dental and Craniofacial Research
H. Nelson Aguila, National Cancer Institute

8:00 a.m. **Hypoxia Imaging in Head and Neck Cancer**
Kenneth Krohn, University of Washington, Seattle

8:15 a.m. **Tumor Therapies Targeting the Tumor-Specific EGFRvIII Mutation**
John Sampson, Duke University

8:30 a.m. **Fluorescence Spectroscopy and Imaging for Noninvasive Oral Cancer Diagnosis**
Ann Gillenwater, University of Texas M.D. Anderson Cancer Center

8:45 a.m. **New Directions in the University of Texas M.D. Anderson Cancer Center Head and Neck SPORE**
Scott Lippman, University of Texas M.D. Anderson Cancer Center

9:30 a.m. **Break**

9:45 a.m. **New Directions in the Johns Hopkins University Head and Neck SPORE**
David Sidransky, Johns Hopkins University

10:30 a.m. **New Directions in the University of Michigan Head and Neck SPORE**
Gregory Wolf, University of Michigan

11:15 a.m. **The New Head and Neck SPORE at Emory University**
Dong Shin, Emory University

**Hematological Malignancies Grand Ballroom IV
(Leukemia, Lymphoma, Myeloma)**

Chairs: *Jean-Pierre Issa, University of Texas M.D.
Anderson Cancer Center*

*NIH
Facilitator:* *Rebecca Huppi, National Cancer
Institute*

8:00 a.m. **Immune Regulations in Multiple
Myeloma**
*Nikhil Munshi, Dana-Farber Cancer
Institute*

8:20 a.m. **Future Directions in Proteasome
Inhibitor Therapies**
*Dharminder Chauhan, Dana-Farber/
Harvard Cancer Center*

8:40 a.m. **Epigenetic Therapy of Leukemias and
Myelodysplastic Syndromes**
*Jean-Pierre Issa, University of Texas M.D.
Anderson Cancer Center*

9:00 a.m. **Epigenetic Markers for Disease
Classification**
*Jaroslav Jelinek, University of Texas M.D.
Anderson Cancer Center*

9:20 a.m. **Protein Lysate Arrays**
*Steven Kornblau, University of Texas
M.D. Anderson Cancer Center*

9:40 a.m. **Discussion**

11:00 a.m. **Adjournment**

Lung**Essex A-C****SPORE Highlights**

Best abstracts from new/junior investigators and new approaches are selected from submitted abstracts.

Chairs: *Paul Bunn, Jr., University of Colorado*
Steven Dubinett, University of California, Los Angeles

NIH Facilitator: *James Jacobson, National Cancer Institute*

Biomarkers for Risk: Chemoprevention Plus Therapy Prediction

Chair: *Adi Gazdar, University of Texas Southwestern Medical Center*

9:00 a.m. ***Histology - Pathologic Classification***
Wilbur Franklin, University of Colorado

9:15 a.m. ***Histology as Response Marker***
John Kittelson, University of Colorado

9:30 a.m. ***Roswell Park Effort***
Mary Reid, Roswell Park Cancer Institute

9:45 a.m. ***Vancouver Scoring System***
Stephen Lam, BC Cancer Agency

10:00 a.m. ***Ki-67 as Chemoprevention Marker***
Fred Hirsch, University of Colorado

10:15 a.m. **Discussion**

10:30 a.m. **Break**

Risk Biomarkers for Lung Cancer

Chairs: *David Carbone, Vanderbilt University*
William Bigbee, University of Pittsburgh

10:45 a.m. ***FISH Biomarkers for Lung Cancer***
Marileila Garcia, University of Colorado

11:00 a.m. ***Sputum Methylation Markers for Lung Cancer***
Steven Belinsky, Lovelace Respiratory Research Institute

mRNA and miRNA Biomarkers for Lung Cancer

11:15 a.m. *Lung Cancer mRNA Expression Profiles*
Joseph Nevins, Duke University

11:45 a.m. *Lung Cancer miRNA Expression Profiles*
Alexander Pertsemlidis, University of Texas Southwestern Medical Center

12 noon **Discussion**

Ovarian

Kent A-C

Chair: Nicole Urban, Fred Hutchinson Cancer Research Center

NIH Facilitators: Michael Birrer and Padma Maruvada, National Cancer Institute

8:00 a.m. **Introduction**
Nicole Urban, Fred Hutchinson Cancer Research Center

8:15 a.m. **RCT of Aspirin To Reduce Breast Density**
Anne McTiernan, Fred Hutchinson Cancer Research Center

8:45 a.m. **Fallopian Tube Lesions as Precursors for Serous Cancer**
Christopher Crum, Dana-Farber Cancer Institute

9:15 a.m. **Clinical Proteomics Trial (NCI Initiative) SPORE Collaboration Update (NCI)**
Elise Kohn, National Cancer Institute Initiative Representative

9:45 a.m. **CA125 as a "Risk Prediction" Marker**
Nicole Urban, Fred Hutchinson Cancer Research Center

10:15 a.m. **Ovarian Cancer Prevention: What Are the Possibilities?**
Thomas Hamilton, Fox Chase Cancer Center

10:45 a.m. **Dietary Risk Factors for Ovarian Cancer**
Shelley Tworoger, Dana-Farber/Harvard Cancer Center

11:15 a.m. **Discussion**

Prostate

Grand Ballroom VIII-IX

Chairs: Peter Scardino, Memorial Sloan-Kettering Cancer Center
William Nelson, Johns Hopkins University

NIH Facilitators: Alison Martin, William Dahut, Suresh Mohla, National Cancer Institute

8:00 a.m. **Profiling Technologies and Standardization**
Joe Gray, Lawrence Berkeley National Laboratory

8:30 a.m. **Second Prostate SPORE Working Group Sessions**
Bone Metastasis Working Group
Evan Keller, University of Michigan
Sue-Hwa Lin, University of Texas M.D. Anderson Cancer Center

Imaging Working Group
Brian Davis, Mayo Clinic, Rochester
John Kurhanewicz, University of California, San Francisco

Experimental Therapeutics Working Group
Howard Scher, Memorial Sloan-Kettering Cancer Center
Christopher Logothetis, University of Texas M.D. Anderson Cancer Center

Resources and Specimen Working Group
Bruce Trock, Johns Hopkins University

9:30 a.m. **Biomarkers, IPBS, caBIG Initiative**
Bruce Trock, Johns Hopkins University
Robert Dennis, University of California, Los Angeles
Ian Fore, National Cancer Institute

- 10:15 a.m. **Development of Novel Therapies in the SPORE Environment**
Timothy Thompson, University of Texas M.D. Anderson Cancer Center
Christopher Logothetis, University of Texas M.D. Anderson Cancer Center
- Summary Presentations of Working Group Recommendations and Plans**
- 11:00 a.m. **Bone Metastasis Working Group**
Evan Keller, University of Michigan
Sue-Hwa Lin, University of Texas M.D. Anderson Cancer Center
- 11:15 a.m. **Imaging Working Group**
Brian Davis, Mayo Clinic, Rochester
John Kurhanewicz, University of California, San Francisco
- 11:30 a.m. **Experimental Therapeutics Working Group**
Howard Scher, Memorial Sloan-Kettering Cancer Center
Christopher Logothetis, University of Texas M.D. Anderson Cancer Center
- 11:45 a.m. **Resources and Specimen Working Group**
Bruce Trock, Johns Hopkins University

Skin**Grand Ballroom I**

Chair: Ruth Halaban, Yale University

NIH Facilitators: Magdalena Thurin and Devi Vembu, National Cancer Institute

Novel Molecular Targets for Melanoma

Moderators: Keith Flaherty, The Wistar Institute/ University of Pennsylvania
James Mier, Beth Israel Deaconess Medical Center

8:00 a.m. **NOTCH/Wnt Pathway and Inhibitors**
Meenhard Herlyn, The Wistar Institute/ University of Pennsylvania

8:20 a.m. **Akt Pathway and Inhibitors**

Biology of Akt in Melanoma
Michael Davies, University of Texas M.D. Anderson Cancer Center

- Akt/PI3K Inhibitors
Peter Lebowitz, GlaxoSmithKline
- 8:40 a.m. ***Src Kinase Pathway and Inhibitors***
Src Kinase Inhibitors
Lewis Strauss, Bristol-Myers Squibb Company
- 9:00 a.m. ***iNOS Pathway and Inhibitors***
iNOS, a Marker of Poor Prognosis, Now a Target for Therapy
Elizabeth Grimm, University of Texas M.D. Anderson Cancer Center

Clinical Data From the Phase I Trial With iNOS Inhibitors
Colin Meyer, Reata Pharmaceuticals, Inc.
- 9:20 p.m. ***FGFR Inhibitors Pathway and Inhibitors***
Kevin Kim, University of Texas M.D. Anderson Cancer Center
- 9:45 a.m. **Break**
- Immunotherapy Monoclonal Immunomodulating Antibodies**
Moderator: Mario Sznol, Yale University
- 10:00 a.m. ***Introduction***
Mario Sznol, Yale University
- 10:05 a.m. ***Anti-CTLA4 Therapy***
James Allison, Memorial Sloan-Kettering Cancer Center
- 10:25 a.m. ***Anti-PD1 Therapy***
Alan Korman, Medarex
- 10:45 a.m. ***Anti-CD40 Therapy***
Keith Flaherty, The Wistar Institute/ University of Pennsylvania
- 11:05 a.m. ***Anti-CD137 Therapy***
Lieping Chen, Johns Hopkins School of Medicine
- 11:25 a.m. ***Issues in Combinations of Antibody Therapy***
Rachel Humphrey, Bristol-Myers Squibb Company
-

Uterine**Waterview C-D**

Chair: Thomas Burke, University of Texas M.D. Anderson Cancer Center

NIH Facilitator: Samir Khleif, National Cancer Institute

NCI Presentations

8:00 a.m. *Intramural Program*

8:15 a.m. *Major Initiative*

8:30 a.m. *Discussion*

Animal Models of Endometrial Cancer

Chair: Russell Broaddus, University of Texas M.D. Anderson Cancer Center

8:45 a.m. *Activation of Akt via Dysregulation of IGF-I Signaling in the Endometrium of Neonatal DES-Exposed Rodents*
Adrienne McCampbell, University of Texas M.D. Anderson Cancer Center

9:30 a.m. *Mig-6 Modulates Uterine Steroid Hormone Responsiveness and Exhibits Altered Expression in Endometrial Disease*
Jae-Wook Jeong, Baylor College of Medicine
Francesco DeMayo, Baylor College of Medicine

10:15 a.m. **Break**

10:30 a.m. *Mouse Model of Type II Endometrial Carcinogenesis*
Diego Castrillon, University of Texas Southwestern Medical Center

11:15 a.m. *Mouse Model of Endometrial Tumorigenesis Is Useful for Identification of Potential Molecular Marker of Invasive Disease*
Lora Ellenson, Cornell University

12 noon **Break**

12:15 p.m. **Discussion**

Workshop Adjournment

12 noon

Translational Breast Cancer Research Consortium (*closed meeting*)

12 noon - 6:00 p.m.

Harborside D

Planning Committee

Kenneth Anderson, M.D., Director, Myeloma SPORE
Dana-Farber/Harvard Cancer Center

Michael Atkins, M.D., Director, Kidney SPORE
Dana-Farber/Harvard Cancer Center

Mitchel Berger, M.D., Director, Brain Tumor SPORE
University of California, San Francisco

Paul Bunn, Jr., M.D., Director, Lung SPORE
University of Colorado Cancer Center

Thomas Burke, M.D., Director, Uterine SPORE
University of Texas M.D. Anderson Cancer Center

Robert Coffey, Jr., M.D., Director, GI SPORE
Vanderbilt University

Deborah Collyar, Co-Leader
Patient Advocate Research Team Program

Nancy Davidson, M.D., Director, Breast SPORE
Johns Hopkins University

James Engh, Patient Advocate, Prostate SPORE
Mayo Clinic, Rochester

Stephen Forman, M.D., Director, Lymphoma SPORE
Beckman Research Institute at City of Hope

Cindy Geoghegan, Patient Advocate, Breast SPORE
Johns Hopkins University

Jennifer Grandis, M.D., Director, Head and Neck SPORE
University of Pittsburgh

Ruth Halaban, M.D., Director, Skin SPORE
Yale University

James Ingle, M.D., Director, Breast SPORE
Mayo Clinic, Rochester

Jean-Pierre Issa, M.D., Director, Leukemia SPORE
University of Texas M.D. Anderson Cancer Center

Gary Kelloff, M.D., Special Advisor
National Cancer Institute

John Minna, M.D., Director, Lung SPORE
University of Texas Southwestern Medical Center/
M.D. Anderson Cancer Center

Lori Monroe, Patient Advocate, Lung SPORE
Vanderbilt-Ingram Cancer Center

William Nelson, M.D., Ph.D., Director, Prostate SPORE
Johns Hopkins University

Gloria Petersen, Ph.D., Director, Pancreatic SPORE
Mayo Clinic, Rochester

Jane Reese-Coulbourne, Patient Advocate
Advocate Partners

Peter Scardino, M.D., Director, Prostate SPORE
Memorial Sloan-Kettering Cancer Center

Nicole Urban, Sc.D., Director, Ovarian SPORE
Fred Hutchinson Cancer Research Center

National Institutes of Health Facilitators

Jeffrey Abrams, M.D.

H. Nelson Aguila, D.V.M.

Michael Birrer, M.D., Ph.D.

William Dahut, M.D.

Keyvan Farahani, Ph.D.

Jane Fountain, Ph.D.

Rebecca Huppi, Ph.D.

James Jacobson, Ph.D.

Gary Kelloff, M.D.

Samir Khleif, M.D.

Alison Martin, M.D.

Padma Maruvada, Ph.D., M.P.H.

Suresh Mohla, Ph.D.

Yasaman Shirazi, Ph.D.

Malcolm Smith, M.D., Ph.D.

Shamala Srinivas, Ph.D.

Magdalena Thurin, Ph.D.

Devi Vembu, Ph.D.

Barbara Vonderhaar, Ph.D.

Paul Wagner, Ph.D.

Roy Wu, Ph.D.

Heng Xie, M.D., Ph.D.

Organ Systems Branch

Jorge Gomez, M.D., Ph.D., Chief

Teri Brown, Program Coordinator

Sarah Fabian, Program Coordinator

Rajeev Agarwal, Ph.D., Program Director

Ivan Ding, M.D., Program Director

Andrew Hruszkewycz, M.D., Ph.D., Program Director

Igor Kuzmin, Ph.D., Program Director

Peter Ujhazy, M.D., Ph.D., Program Director

SPORE Directors

James Abbruzzese, M.D., Pancreatic SPORE
University of Texas M.D. Anderson Cancer Center

Richard Ambinder, M.D., Ph.D., Lymphoma SPORE
Johns Hopkins University

Kenneth Anderson, M.D., Myeloma SPORE
Dana-Farber/Harvard Cancer Center

Carlos Arteaga, M.D., Breast SPORE
Vanderbilt University

Michael Atkins, M.D., Kidney SPORE
Dana-Farber/Harvard Cancer Center

Robert Bast, M.D., Ovarian SPORE
University of Texas M.D. Anderson Cancer Center

Stephen Baylin, M.D., Lung SPORE
Johns Hopkins University

Mitchel Berger, M.D., Brain Tumor SPORE
University of California, San Francisco

Darell Bigner, M.D., Ph.D., Brain Tumor SPORE
Duke University

Kirby Bland, M.D., Breast SPORE
University of Alabama at Birmingham

Donald Buchsbaum, Ph.D., Pancreatic SPORE
University of Alabama at Birmingham

Paul Bunn, M.D., Lung SPORE
University of Colorado Cancer Center

Thomas Burke, M.D., Uterine SPORE
University of Texas M.D. Anderson Cancer Center

David Carbone, M.D., Ph.D., Lung SPORE
Vanderbilt University

Robert Coffey, Jr., M.D., Gastrointestinal SPORE
Vanderbilt University

Daniel Cramer, M.D., Ovarian SPORE
Brigham and Women's Hospital

Nancy Davidson, M.D., Breast SPORE
Johns Hopkins University

Jean deKernion, M.D., Prostate SPORE
University of California, Los Angeles

Colin Dinney, M.D., Bladder SPORE
University of Texas M.D. Anderson Cancer Center

Steven Dubinett, M.D., Lung SPORE
University of California, Los Angeles

Shelton Earp III, M.D., Breast SPORE
University of North Carolina, Chapel Hill

Stephen Forman, M.D., Lymphoma SPORE
Beckman Research Institute at City of Hope

Charles Fuchs, M.D., M.P.H., Gastrointestinal SPORE
Dana-Farber/Harvard Cancer Center

Eugene Gerner, Ph.D., Gastrointestinal SPORE
University of Arizona

G. Yancey Gillespie, Ph.D., Brain Tumor SPORE
University of Alabama at Birmingham

Jennifer Grandis, M.D., Head and Neck SPORE
University of Pittsburgh

Joe Gray, Ph.D., Breast SPORE
University of California, San Francisco

Elizabeth Grimm, Ph.D., Skin SPORE
University of Texas M.D. Anderson Cancer Center

Ruth Halaban, M.D., Skin SPORE
Yale University

Meenhard Herlyn, D.V.M., Sc.D., Skin SPORE
The Wistar Institute/University of Pennsylvania

Helen Heslop, M.D., Lymphoma SPORE
Baylor College of Medicine

Gabriel Hortobagyi, M.D., FACP, Breast SPORE
University of Texas M.D. Anderson Cancer Center

J. Dirk Iglehart, M.D., Breast SPORE
Dana-Farber/Harvard Cancer Center

James Ingle, M.D., Breast SPORE
Mayo Clinic, Rochester

Jean-Pierre Issa, M.D., Leukemia SPORE
University of Texas M.D. Anderson Cancer Center

Bruce Johnson, M.D., Lung SPORE
Dana-Farber/Harvard Cancer Center

Philip Kantoff, M.D., Prostate SPORE
Dana-Farber/Harvard Cancer Center

Scott Kern, M.D., Gastrointestinal SPORE
Johns Hopkins University

Thomas Kupper, M.D., Skin SPORE
Brigham and Women's Hospital

Paul Lange, M.D., Prostate SPORE
University of Washington/
Fred Hutchinson Cancer Research Center

Chung Lee, Ph.D., Prostate SPORE
Northwestern University

Scott Lippman, M.D., Head and Neck SPORE
University of Texas M.D. Anderson Cancer Center

Christopher Logothetis, M.D., Prostate SPORE
University of Texas M.D. Anderson Cancer Center

H. Kim Lyerly, M.D., Breast SPORE
Duke University

John Minna, M.D., Lung SPORE
University of Texas Southwestern Medical Center/
M.D. Anderson Cancer Center

William Nelson, M.D., Ph.D., Prostate SPORE
Johns Hopkins University

Olufunmilayo Olopade, M.D., Breast SPORE
University of Chicago

Brian O'Neill, M.D., Brain Tumor SPORE
Mayo Clinic, Rochester

C. Kent Osborne, M.D., Breast SPORE
Baylor College of Medicine

Robert Ozols, M.D., Ph.D., Ovarian SPORE
Fox Chase Cancer Center

Gloria Petersen, Ph.D., Pancreatic SPORE
Mayo Clinic, Rochester

Kenneth Pienta, M.D., Prostate SPORE
University of Michigan

Peter Scardino, M.D., Prostate SPORE
Memorial Sloan-Kettering Cancer Center

Dong Shin, M.D., Head and Neck SPORE
Emory University

Marc Shuman, M.D., Prostate SPORE
University of California, San Francisco

David Sidransky, M.D., Head and Neck SPORE
Johns Hopkins University

Jill Siegfried, Ph.D., Lung SPORE
University of Pittsburgh

Joel Tepper, M.D., Gastrointestinal SPORE
University of North Carolina, Chapel Hill

Timothy Thompson, Ph.D., Prostate SPORE
Baylor College of Medicine

Donald Tindall, Ph.D., Prostate SPORE
Mayo Clinic, Rochester

Nicole Urban, Sc.D., Ovarian SPORE
Fred Hutchinson Cancer Research Center

George Weiner, M.D., Lymphoma SPORE
University of Iowa-Mayo Clinic

Gregory Wolf, M.D., Head and Neck SPORE
University of Michigan

T.-C. Wu, M.D., Ph.D., Cervical SPORE
Johns Hopkins University

